BMY - Bristol-Myers Squibb Company
| Previous close | 45.24 |
| Open | 45.34 |
| Bid | 45.31 x 800 |
| Ask | 45.32 x 1100 |
| Day's range | 44.95 - 45.38 |
| 52-week range | 44.30 - 63.69 |
| Volume | 5,375,334 |
| Avg. volume | 18,828,661 |
| Market cap | 74.018B |
| Beta (3Y monthly) | 0.87 |
| PE ratio (TTM) | 15.05 |
| EPS (TTM) | 3.01 |
| Earnings date | 25 Apr 2019 |
| Forward dividend & yield | 1.64 (3.44%) |
| Ex-dividend date | 2019-04-04 |
| 1y target est | 57.80 |
- Zacks•3 hours ago
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
- Zacks•3 hours ago
Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
- Zacks•4 hours ago
Bristol-Myers (BMY) Moves to Buy: Rationale Behind the Upgrade
Bristol-Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks•5 hours ago
Top 5 ROE Stocks to Buy on Better-Than-Expected Q1 Earnings
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
- Zacks•yesterday
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
- Motley Fool•3 days ago
How Marijuana Legalization Affected OrganiGram and Aphria's Latest Results
These two marijuana stocks reported very different results last quarter. Plus, how Abbott's challenging Dexcom in diabetes, and what's next for Bristol-Myers following its Celgene acquisition.
- Motley Fool•3 days ago
3 Cancer Treatment Stocks to Buy in April
These three cancer stocks have tremendous upside potential.
- Motley Fool•4 days ago
5 Top Healthcare Stocks to Buy in 2019
Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.
- Zacks•5 days ago
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•6 days ago
Bristol-Myers Squibb Company (NYSE:BMY): Immense Growth Potential?
Looking at Bristol-Myers Squibb Company's (NYSE:BMY) earnings update in December 2018, analyst consensus outlook appear cautiously optimistic, with earnings expected to grow by...
- Business Wire•6 days ago
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
- Zacks•6 days ago
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
Key highlights of the past week are collaborations and pipeline updates.
- Zacks•7 days ago
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $46.02, marking a -1.03% move from the previous day.
- Motley Fool•7 days ago
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
- Zacks•8 days ago
Bristol-Myers' Shareholders Vote for Celgene Acquisition
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
- Zacks•8 days ago
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
- Reuters•11 days ago
Bristol-Myers says shareholders vote to approve Celgene takeover
By Michael Erman and Svea Herbst-Bayliss NEW YORK (Reuters) - Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion (56.6 billion pounds) acquisition of biotech Celgene Corp ...
- CNBC•11 days ago
Bristol-Myers shareholders approve drugmaker's $74 billion deal with Celgene
The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.
- Business Wire•11 days ago
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Bristol-Myers Squibb Company (BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (CELG) at the Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our shareholders for their support for this combination,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines.
- Zacks•11 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
- Zacks•12 days ago
Seattle Genetics' Adcetris Progresses Well Amid Competition
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
- Business Wire•12 days ago
Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
The U.S. Environmental Protection Agency (EPA) has recognized Bristol-Myers Squibb Company (BMY) with an ENERGY STAR® Partner of the Year Sustained Excellence Award for its outstanding contributions and leadership to improve the energy efficiency of facilities worldwide. Bristol-Myers Squibb has earned the ENERGY STAR® Partner of the Year award for the past five consecutive years. “We are proud to have our commitment to environmental responsibility recognized with the ENERGY STAR Partner of the Year Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, Bristol-Myers Squibb.
- Barrons.com•13 days ago
Bristol-Myers Squibb, JPMorgan Chase, and Other Dividend-Paying Stocks That Could Beat the Market
Columbia fund manager David King also likes a group of convertible preferred-stock issues, which offer higher yields than common shares.
- Zacks•14 days ago
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
Bristol-Myers Squibb (BMY) closed the most recent trading day at $45.98, moving -1.73% from the previous trading session.
